UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen

In a report published Friday, Stifel analyst Stephen Willey terminated coverage on

. In the report, Stifel noted, “We are discontinuing coverage of Onyx Pharmaceuticals due to the company's acquisition by Amgen (AMGN, Covered by our Colleague Joel Sendek, Hold, $115.41) at $125.00 per share in cash. Our last rating on the stock was Hold. Our FY13 estimates for ONXX were EPS of $(2.92) and $626M of revenues.” Onyx Pharmaceuticals closed on Thursday at $124.70.